ObjectiveThe effect of hyperbaric oxygen combined with targeted treatment of human epidermal growth factor receptor (HER) positive patients with advanced gastric cancer. Methods68 cases of HER positive advanced gastric cancer were randomly divided into observation group (38 cases) and control group (30 cases). The control group was given the targeted therapy of trastuzumab. The observation group were given hyperbaric oxygen therapy on the basis of the control group. Abdominal circumference recovery time, recovery time of bowel sound, anal exhaust time and hospitalization time were compared between the two group. The serum IL-37 and IL-39 levels were compared between the two groups after the treatment. ResultsAfter treatment, the observation group were required for the normal recovery time (96.0±3.0) h. The patients in the control group were (120.0±2.0) h. The difference between the two groups was statistically significant (P＜0.01). The bowel sounds recovery time of the observation group was shorter than that of the control group (P＜0.05). At the end of the course of treatment, the levels of serum IL-37 and IL-39 in the two groups were significantly reduced. The serum levels of IL-37 and IL-39 in the observation group were lower than those in the control group, and the difference was statistically significant (P＜0.05). ConclusionHyperbaric oxygen combined with targeted therapy can promote the bowel sound recovery and exhaust defecation of HER positive patients with advanced gastric cancer, accelerate the recovery of gastrointestinal function, relieve abdominal distention. It can reduce the residual gastric cancer cells and ascites, and reduce the level of IL-37 and IL-39 that regulates the growth of tumor cells.

无